Research Article: Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study
Abstract:
Introduction: Multiple myeloma (MM) is a leading cause of hematopoietic cancer-related mortality, accounting for 20% of deaths. MM-targeted therapies have demonstrated efficacy, and since 2015, the United States Food and Drug Administration (FDA) has approved five targeted drugs. However, their cardiovascular safety has not been comprehensively evaluated.
Introduction:
Objective: This study aimed to investigate the association between MM-targeted therapy and cardiovascular adverse events (AEs).
Read more